Do new cancer drugs offer good value for money? the perspective of oncologists, payers, patients, and general population
Abstract
Authors
T. Dilla L. Lizán S. Paz P. Garrido C. Avendaño J.J. Cruz J. Espinosa J.A. Sacristan
T. Dilla L. Lizán S. Paz P. Garrido C. Avendaño J.J. Cruz J. Espinosa J.A. Sacristan
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now